Advantage Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Advantage Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11	Closed	-$1K	–	1032
2017 Q4	$1K	Buy	+11	New	+$628	﹤0.01%	963
2016 Q3	–	Sell	-43	Closed	–	–	939
2016 Q2	$0	Hold	43	–	–	﹤0.01%	894
2016 Q1	$0	Hold	43	–	–	﹤0.01%	891
2015 Q4	$1K	Hold	43	–	–	﹤0.01%	825
2015 Q3	$3K	Hold	43	–	–	﹤0.01%	718
2015 Q2	$3K	Hold	43	–	–	﹤0.01%	742
2015 Q1	$3K	Hold	43	–	–	﹤0.01%	745
2014 Q4	$4K	Buy	+43	New	+$4.45K	﹤0.01%	642

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Advantage Investment Management's MDGL Position: Q1 2018 in Review

Advantage Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2018, closing a stake of 11 shares — an estimated $1K sold.

Advantage Investment Management first reported a position in MDGL in Q4 2014 and held it in 8 quarters. The position peaked at $4K in Q4 2014. 100 funds tracked by Wall St. Rank hold MDGL as of Q1 2018.

Advantage Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Advantage Investment Management sold 11 Madrigal Pharmaceuticals shares in Q1 2018, an estimated $1K.
Advantage Investment Management first reported a position in Madrigal Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Advantage Investment Management's Madrigal Pharmaceuticals position peaked at $4K in Q4 2014.
100 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2018.

Based on Advantage Investment Management's 13F filing for Q1 2018, filed 15 May 2018.